To characterize somatic alterations in colorectal cancer (CRC), we conducted a genome-scale analysis of 106 CRC specimens. We assessed comprehensive somatic copy number alterations (SCNAs) in these CRC specimens. In addition, we examined microsatellite instability (MSI; low and high), genetic mutations (KRAS, BRAF, TP53, and PIK3CA), and DNA methylation status (classified into low, intermediate, and high type).
| 451 methylator phenotype (CIMP). [2] [3] [4] Moreover, most cases of CRC can be explained by a combination of these three pathways occurring in the colorectum. [3] [4] [5] [6] Many advances in molecular analyses have also been made in CRC. 7 Recent studies have described novel molecular classifications based on gene expression, including consensus molecular subtypes and colorectal subtyping associated with cellular phenotypes and responses to therapy. [8] [9] [10] These hypotheses provide novel insights into the molecular features of colorectal carcinogenesis. [7] [8] [9] Accumulation of genomic alterations is closely associated with the progression of CRC. 11 For example, somatic copy number alterations (SCNAs) that characterize the CIN pathway are involved in the progression of CRC. 11, 12 Specific mutations, including mutations in APC, KRAS, PIK3CA, and TP53, are frequently detected in CRC with the CIN-phenotype and may be associated with accumulation of SCNAs, playing only a minor role in the progression of CRC with the MIN type 13 because accumulation of numerous mutations within the whole genome, rather than SCNAs, is important for the progression of the MIN type of CRC. 6, 7 Specific mutations in BRAF and KRAS have also been shown to be closely related to CRC with the MIN-phenotype. 6 ,7 CIMP-low or -intermediate status is
primarily found in CIN-type CRC, 13 whereas acquisition of the CIMP-high status is closely associated with MIN-type CRC. 13 CIMP markers have been developed for prediction of genome-wide methylation levels in tumor cells, [14] [15] [16] 2 | METHODS
| Patients
A total of 106 samples (excluding intramucosal and submucosal cancers) were obtained from patients with newly diagnosed primary CRC at Iwate Medical University between 2011 and 2016. These samples were from resected specimens, and the patients had not received prior chemotherapy.
The pathological diagnosis and staging were determined according to a combination of a Japanese classification and the modified Dukes'
classification. 17 The detailed clinicopathological findings are listed in Table 1 .
This study was approved by the Ethical Research Committee, Iwate Medical University.
| Crypt isolation
Fresh tumor and normal tissues were obtained from resected CRC tissues. Normal colonic mucosa was collected from the most distal portion of the colon.
Crypt isolation from the tumor and normal mucosa was performed as previously reported. 18 Briefly, fresh mucosa and tumor tissues were minced with a razor into small pieces and incubated at 37°C for 30 min in calcium-and magnesium-free Hanks' balanced salt solution (CMF) containing 30 mM ethylenediaminetetraacetic acid (EDTA). The isolated crypts were immediately fixed in 70% ethanol and stored at 4°C until used for DNA extraction.
The fixed isolated crypts were observed under a dissecting microscope (SZ60; Olympus, Tokyo, Japan). The tumor samples were collected primarily from the central area of tumor ulceration because the invasive front, which was thought to determine the invasive ability of the tumor cells, was observed in the central area. 19 In addition, considerable cancerous glands were present in this area.
Some isolated crypts were routinely processed by histopathological analysis to confirm the histological nature of the isolated glands. Contamination, such as interstitial cells, was not evident in any of our 106 samples. 
| Analysis of MSI
The DNA was amplified by polymerase chain reaction (PCR) with fluorescent dye-labeled primers targeting five microsatellites, including BAT25, BAT26, D5S346, D2S123, and D17S250. The DNA was analyzed using a DNA sequencer (ABI PRISM-310 Genetic Analyzer;
ABI, Foster City, CA), and microsatellite fragment analyses were performed using a GeneScan software (ABI). MSI status was determined by the presence of additional bands in the PCR product from tumor DNA. MSI-high (MSI-H) status was defined as instability in at least two of the five microsatellite loci, whereas MSI-low (MSI-L) was defined as instability in only one locus. In addition, MSI-negative was defined as having no shifted loci according to NCI criteria. 20 However, in the present study, tumors categorized as MSI-L and MSInegative were considered MSS in this analysis.
| Analysis of KRAS and BRAF mutations
Mutations in KRAS (codons 12 and 13) and BRAF (V600E) genes were analyzed using a CE-IVD marked PyroMark (Qiagen, Hilden, Germany)
according to the manufacturer's protocols (Therascreen KRAS Pyro Kit
Handbook, version 1, July 2011). The primers used in the present study were described previously. 21 The cut-off value for the mutation assay was 15% mutant alleles. Each PCR product was examined by pyrosequencing using PyroMark Gold Q96 reagents, Streptavidin
Sepharose High Performance (GE Healthcare Bio-Science AB, Uppsala, Sweden) and a PyroMark Q24 instrument (Qiagen) with PyroMark Q24 1.0.6.3 software.
| Analysis of TP53 and PIK3CA mutations
Mutations in the TP53 gene in exons 5-8 and the PIK3CA gene in exons 9 and 20 were examined by PCR single-stranded conformation polymorphism (PCR-SSCP), with some modifications. 12 Mutations obtained by SSCP in the TP53 and PIK3CA genes were then analyzed by sequence analysis. Briefly, PCR was used to amplify exons 5-8 of the TP53 gene and exons 9 and 20 of the PIK3CA gene. The conditions for PCR were described previously. 22 Briefly, the PCR products (2 µL)
were mixed with 10 µL of gel loading solution (9.5% deionized formamide, 20 mM EDTA-Na, 0.05% xylene cyanol, and bromphenol blue), denatured at 95°C for 5 min, and then kept on ice until loading.
Nondenaturing 7.5% polyacrylamide gels were used for electrophoresis, which was performed at 260-300 V and 22°C for 3-12 h using a temperature controller (Resolmax, ATTO Co., Tokyo). The gels were visualized by silver staining and photographed. The migrated band was removed from the gel, and the DNA was extracted. The sequence was determined by direct sequencing, as previously described. Additionally, LRR and BAF data were used to identify regions of hemizygous and copy-neutral LOH.
In the present study, we classified copy number alterations into three types, including copy number gains (CN-gains), copy numberloss of heterozygosity (LOH), and copy neutral-LOH. 12 
| Statistical analysis
Hierarchical analysis was performed for clustering the samples according to the SCNA pattern in order to achieve maximal homogeneity for each group and the highest difference between groups. The clustering algorithm was set to centroid linkage clustering, the standard hierarchical clustering method used in biological analyses.
The method was described elsewhere.
Data obtained for histological features, mutations, methylation, and SCNA status based on each subgroup were analyzed using chi-square tests with Yates' corrections with the aid of Stat Mate-III software (Atom, Tokyo, Japan). Differences in age distributions between the two groups were analyzed using Mann-Whitney U tests (PRISM6; GraphPad software, La Jolla, CA). Differences with P values of less than 0.05 were considered significant.
| RESULTS
In the present study, hierarchical clustering analysis based on the SCNA pattern, including gains, LOHs, and copy-neutral LOHs, was carried out to examine differences in genetic alterations in samples from patients with CRC.
Three distinct subgroups were categorized, as shown in Figure 1 .
The vertical line shows SCNAs, and the horizontal lines denote "relatedness" between samples and SCNAs at the chromosomal loci.
The CRCs examined in this study were categorized into three distinct patterns in the cluster analysis.
The clinical findings in each subgroup categorized based on SCNAs are listed in Table 2 . The frequency of right-sided CRC was significantly higher in subgroup 1 than in subgroup 3.
| SCNAs in CRCs we examined
The mean total number of chromosomal aberrations per patient was LOHs (range: 9-328). There were significant differences in the total numbers of CNAs between subgroups 1 and 2 or 3 (P < 0.01).
Moreover, significant differences were observed in the average numbers of CN gains between subgroups 1 and 2 or 3 (P < 0.01).
Although LOH was common between the three subgroups, there were significant differences in the average numbers of CN LOHs between subgroups 2 and 1 or 3 (P < 0.01).
Regions of gains detected in more than 50% of cases were located at 20q11. Table 3 .
| Differences in SCNAs between subgroups
Next, we examined differences in SCNAs between the three subgroups.
Regions of gain detected in more than 50% of cases were selected for comparison of each group. We also examined regions of loss found in more than around 30% of cases in the three subgroups.
Significant differences in gains between subgroups 2 and 3 were found at 1q23. Table 4 ).
Significant differences in the frequencies of copy-neutral LOH between subgroups 2 and 3 were found at 12p12.2-13.1, 1q24.3-25.1, and 10q22.1 (subgroup 3 < subgroup 2; Table 4 ). However, no differences in the frequency of LOH were found between the three subgroups.
Significant differences in the frequencies of CN gains were observed between subgroups 1 and 2 at 2q, 2p, 3q, 3p, 5p, 4q, 4p, 21q, 19q, and 19p
(Supplementary Table S1 ). Although no significant differences in LOH were observed between subgroups 1 and 2, significant differences in copy-neutral LOH at 5q31-33, 5q21-22, 22q11-12, 17q21-25, 17p11-13, and 12p11-12 were found between subgroups 1 and 2.
Finally, we examined significant differences in the frequencies of Table S2 ). There were significant differences in the frequencies of CN-LOH at 17q24-25 and 17p11-13 between subgroups 1 and 3. However, no significant differences in LOH were found between subgroups 1 and 3.
When regions of gains detected in more than 40% of cases were selected for comparisons of the groups, common SCNAs between the three subgroups were gains at 7p15.2, 7q11-12, 8q21-24, 20q11-13, and LOHs of 17p11, and 18p/q.
3.4 | Differences in MSI, mutations in cancer-related genes, and methylation statuses between subgroups 1, 2, and 3
The frequency of MSI-high status was significantly higher in subgroup 1 than in subgroup 3. However, there were no significant differences in the frequencies of MSI-high status between subgroups 2 and 3. Next, we examined mutations in TP53, KRAS, BRAF, and PIK3CA in subgroups 1, 2, and 3. The frequency of KRAS mutation was significantly higher in subgroup 3 (20/30, 66.7%) than in subgroup 1 (21/59, 35.6%; P = 0.02). In addition, TP53, BRAF, and PIK3CA mutations were not correlated with subgroups 1, 2, or 3. Finally, we analyzed methylation statuses in subgroups 1, 2, and 3 and found that there were no significant differences in the frequencies of methylation statuses among the subgroups. These results are summarized in Table 5 .
| DISCUSSION
CRC results from the accumulation of somatic CNAs. [23] [24] [25] Genomewide analysis of SCNAs provides opportunities for identifying cancer driver genes in an unbiased manner. 11 Recent studies have shown that many molecular mechanisms affect the development of CRC, 7, 8, 10, 12, 13 contributing to advancements in approaches for the clinical diagnosis and treatment of CRC. 8, 10 Our current data indicated that there were three molecular patterns based on SCNAs, as identified by high-throughput genomic analysis. Thus, analysis of the molecular patterns of CRC according to SCNAs may help us to understand the characteristics of colorectal carcinogenesis. 11 We showed that the three patterns established based on SCNA patterns were closely associated with clinicopathological and molecular findings in CRCs.
Moreover, our study confirmed that molecular alterations based on SCNAs converged into three different patterns during colorectal progression.
A previous study showed that there are two molecular types of colorectal carcinogenesis, including MSS and MIN. 17 Thus, we suggest that the main alteration governing the molecular mechanisms of CRC is oncogenic potential.
Most CRCs examined in this study were subgroup 1 tumors characterized by a low frequency of SCNAs. In addition, subgroup 1 was closely associated with a high frequency of MSI-high, BRAF mutations, and high methylation status compared with subgroups 2 and 3, although differences in the frequencies of BRAF mutations and HME were not significant. CN gains at 7p15. Previous studies have shown that multiple SCNAs are frequently found in CRCs. [23] [24] [25] In the present study, we found significant differences in gains and LOHs between subgroups 2 and 3, which were characterized by multiple SCNAs. This finding suggested that different patterns existed 30 and MSI1 (Musashi-1; 12q24) 31 may be suitable as candidate genes that are responsible for the gains. Notably, a prior report showed that overexpression of MAP3K8 is correlated with poor prognosis in patients with early-onset CRC. 28 Additionally, a separate study showed that 5-Lox is upregulated in CRC and that inhibition of 5-Lox expression may be valuable for the prevention and treatment of CRC. 29 Another previous study revealed that LIG4, a DNA ligase in DNA double-strand break repair, is a direct target of β-catenin and that blocking LIG4
sensitizes CRC cells to radiation. 30 Moreover, LIG4 is highly upregulated in human CRC cells through β-catenin hyperactivation, which is closely associated with Wnt signal activation. 30 This finding suggests that LIG4 plays a specific role in Wnt signaling-induced radioresistance in CRC. 30 Finally, a recent study showed that the stem cell marker MSI1 is overexpressed in many cancer types, including CRC. 31, 32 MSI1 is highly expressed in primary colon tumors and metastatic lesions in the lymph nodes as compared with that in paired adjacent normal colon mucosal tissue. 31, 32 We suggest that these candidate genes located at 10q11 and consistent with a previous study reported by Kaneda and Yagi 16 suggested that considerable DNA methylation may be required for the development of CRC. In addition, our data showed that CRC arose as a consequence of the accumulation of genetic and epigenetic alterations during neoplastic transformation.
There are some limitations to our study. First, The Cancer Genome Atlas (TCGA) provides representative data for CRCs. 7 Although TCGA platform is different from that of the present study, 7 it is important to compare molecular alterations from TCGA database with those of the present study. The molecular patterns we proposed were different from those of TCGA, as shown in our current findings. In TCGA, molecular alterations were also subclassified into hypermutated and non-hypermutated type. 7 Our data indicated that although molecular pathways could be divided into three subgroups based on SCNAs, hypermutated, and non-hypermutated types corresponded to the MSI type in subgroup 1 and the remaining tumors in subgroup 1 plus tumors in subgroups 2 and 3, respectively. In addition, our classification was characterized by distinct clinicopathological and molecular findings.
We believe that the present findings are useful to evaluate the molecular basis of colorectal carcinogenesis. Second, association of In conclusion, we used a high-density professional whole-genome SCNA array that covered more than approximately 300 000 SNPs to define a comprehensive allelotype for a heterogeneous group of sporadic CRCs based on SCNAs. In the present study, we found that CRC could be classified into three phenotypes (subgroups 1, 2, and 3) determine the impact of these SCNAs on the outcomes of the disease.
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